International Society for Stem Cell Application ISSCA to Launch Postgraduate Studies Program in Stem Cell Therapies and Regenerative Medicine in Collaboration with Medicel Chile
ISSCA and Medicel, Inc. have announced plans to launch a post-graduate studies program in stem cell and regenerative medicine, to be conducted in Santiago Chile February 2021.
MIAMI, July 20 , 2020— The international Society for Stem Cell Application ISSCA and Medicel Chile have announced plans to launch a post graduate studies program in stem cell therapies and regenerative medicine in 2020.
The program will include Seven days of intensive, interactive training coursework with classroom instruction and laboratory practice through didactic lectures, hands-on practical experience in laboratory protocols and relevant lessons in regulatory practices. Medicel’s Chief Scientific Officer and Other leading Scientists will teach the coursework and perform laboratory instruction, accompanied by a series of guest lecturers from the Global Stem Cells Group faculty of scientists.
Attendees will receive hands-on training in techniques for a variety of laboratory processes, and gain insight into the inner workings of a cGMP laboratory and registered tissue bank. Regenerative medicine experts with more 15 years of experience in the field will train attendees and provide the necessary tools to implement regulatory and clinical guidelines in a cGMP laboratory setting
The graduate course will be scheduled 3 times during 2020 starting February 23rd
“ Our end goal in Launching this Fellowship program is to help physicians that are looking for really advanced and formal training in Cellular Therapies and Regenerative Medicine — We want to provide them the necessary skills and in depth specialization that is lacking in our smaller point of care programs ,” noted Benito Novas ISSCA Public Relations Director
To learn more about the February 2020 certification event in Santiago, or any of the other upcoming certification courses around the world, visit the ISSCA website.
About the International Society for Stem Cells Applications (ISSCA)
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine.
Incorporated and Trademarked in the United States of America as a non-profit entity, ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine.
Their code of ethics emphasizes principles of morals and ethical conducts. ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.
About Medicel Chile
Medicel Chile is one of the premiere regenerative medicine treatment centers in the country of Chile, conveniently located in Santiago de Chile, one of the largest metropolitan areas in Latin America. Medicel carries with it a reputation as one of the most scientifically advanced and professional regenerative medicine Laboratories in Chile, and this is in no small part due to its highly-qualified team of scientists and medical professionals and advisers, who research tirelessly to head new breakthroughs in the fields of cellular therapy and cryopreservation, which is the freezing of a stem cell sample to ensure its longevity and freshness, should the patient receiving the service ever wish to use their frozen cells for some future malady.
The Stem Cell Center Network ( a Division of Global Stem Cells Group ) is an international network of regenerative medicine practitioners . Dedicated to promoting the research and development of the field of regenerative medicine, and strives to bring patients cutting-edge treatments that make use of the ever-growing list of benefits that regenerative medicine carry. This week, in a part of their effort to expand their foothold in medical communities around the world, the Stem Cell Center Network has announced the opening of a new training facility in Lisbon, Portugal.
Over the years, the Stem Cell Center Network has sought out to aggressively expand and roll out new membership opportunities, programs, events, and more– an effort that has been redoubled in the last five years. As a result, we have added members that practice regenerative medicine under our banner in over twenty five countries spread across five continents.
The new Portuguese center will be located in the clinic of Dr. Hugo Madeiras, a highly-accredited physician and scientist who will preside over the facility as the Global Stem Cells Group chief representative in Portugal. As the CEO and founder of the Clinic of Advanced Implantology, he focuses exclusively on implantology, esthetics, and digital workflows, and collaborates with over twenty doctors and seventy resources in total. He is also the clinical collaborator for the Straumann Group, a faculty which includes product testing, lecturing, and the creation and delivery of educational content.
Dr. Madeiras graduated from the Instituto Superior de Ciências da Saúde Egas Moniz in Medicine in 2007, and with a Master in Oral Rehabilitation from CESPU in 2009. With his over ten year of experience in the field, he acts as a speaker at several national and international congresses that go over developments and new treatment protocols in the field of dentistry.
“This new center will help in bringing regenerative medicine to the people of Lisbon. It will treat patients with a wide variety of different diseases, but with a special emphasis on Aesthetic Medicine,” Said Benito Novas CEO of the Global Stem Cells Group about the new Stem Cell Center Network partnership, “This new facility will be at the top of the line, a place where Portuguese doctors can come to learn about regenerative medicine protocols, and the advancements that have been made in the field. I am incredibly excited to be working in partnership with Global Stem Cells Group , and look forward to many years as a program leader here in Portugal,”
Stem Cell Center Network plans for the clinic to open in September 2020– and with that date looming closer and closer with each passing week, a date has also been agreed upon for the clinic’s inaugural training– indeed, it will be a place for doctors around the country to convene and learn, share, and research the complexities and applications of regenerative medicine. Barring any extenuating circumstances, the next first Regenerative Medicine Certification Training in the Portuguese clinic will take place on September 25 & 26th, 2020– just weeks after its formal opening. With only 10 spots available, applicants are encouraged to sign up soon for the hands-on training course.
To sign up today, visit: https://issca.us
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
The International Society of Stem Cell Applications (ISSCA) has hereby announced the date of it’s seventh Symposium of Regenerative Medicine. As before, the organization hopes to bring together a network of regenerative medicine practitioners from all over the world to foster a growth of knowledge among them. It will go over a wide range of topics related to regenerative medicine, chiefly among them will be the response of all levels of regenerative medicine research and practice in the COVID-19 pandemic, as well as what the future looks like for the field as a result of it. In addition to this, the symposium will also cover breakthroughs in the field, new treatment options and technological developments that are now available to both doctors and patients.
Cellular Therapies During and After the Pandemic
Cellular therapies have been an invaluable asset in managing the largest pandemic in modern history. This has been evidenced by the use of Mesenchymal cells, along with other growth factors and types of cells, to treat respiratory failure and manage some of the complications induced by exposure to COVID-19. This has resulted in accelerated pathways for regulatory approval and increased funding for new regenerative medicine-based clinical trials.
We are living in a unique time for regenerative medicine, as advancements are being made month after month, year after year at a rapid, exponential rate. Keeping track of the latest advancements in this research and development, and the medical protocols that occur as a result, is critical to safeguarding lives all over the world. Every medical society’s purpose is, primarily, to promote the growth of both their members and the field that they operate in. The International Society for Stem Cell Applications (ISSCA), strives to do just that. In the interest of designing the future of cellular therapies in a post-pandemic world, ISSCA invites pioneers of the field from around the world to form and share in a platform of experiences, knowledge, and progress.
Stem Cells Group to Host Regenerative Medicine Symposium in Buenos Aires, Argentina November 28th
After a period of silence brought about by the global COVID-19 pandemic, the Global Stem Cells Group (GSCG) is prepared to begin bringing medical professionals together by hosting a Regenerative Medicine Symposium in Buenos Aires, Argentina. The Symposium will take place at the Hotel Panamericano, Buenos Aires, on the 28th of November.
The Buenos Aires symposium will feature a wide variety of educational resources, including lectures and demonstrations, as well as product information. All of this is aimed at doctors that are looking to incorporate regenerative medicine into their practices. Industry experts will be on hand to impart the latest information on the newest compounds in the allogeneic stem cell market, including exosomes, amniotic fluid compounds, and umbilical cord blood products. Allogeneic compounds have steadily been increasing in popularity within the field of regenerative medicine, and this is due to their increased safety and treatment efficacy as research has evolved. With this in mind, GSCG representatives will be on hand to give physicians the opportunity to learn more about these popular treatment solutions and how they can be utilized in their own practices.
ISSCA CEO Benito Novas had this to say about the upcoming event: “We’ve barely even scratched the surface of potential for regenerative medicine, which is why it’s so important that we collectively gather and learn about what we’ve done thus far. This is a South
American congress that will witness some of the greatest regenerative doctors of our time
giving once-in-a-lifetime addresses to those in attendance.”
Among these speakers are Drs. Damian Siano, Silvina Pastrana, and Maritza Novas. Dr. Siano will look specifically at sports injuries, and draw on his experience as a sports medicine specialist aiding professional athletes in the world today. Dr. Pastrana, the Medical Director of the Buenos Aires Stem Cells Center, will speak about how stem cells can help to assuage aesthetic conditions. Dr. Novas, an ISSCA Fellow in Cell Therapy and Tissue Engineering, will look at the fundamentals of stem cell biology and their clinical applications. She will cover a broad range of topics concerning MSCs during their transition from bench-side to bedside.
In addition to the wide array of educational sessions offered, the Buenos Aires symposium will also provide a wide array networking and social opportunities for those physicians in attendance. To learn more about ISSCA’s upcoming Buenos Aires Symposium, or to register for the event, visit us at: https://www.issca.us/
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine.
Their code of ethics emphasizes principles of morals and ethical conducts.
At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.
For more information, please visit https://www.issca.us/ or send an email to firstname.lastname@example.org
Global Stem Cells Group announces an agreement with the South Korean biotechnology giant known as Rokit Healthcare to represent the company’s technology in the Latin American market.
The Global Stem Cells Group (GSCG) a world leader in Regenerative Medicine Technologies has signed an agreement with South Korean-based Rokit Healthcare, an esteemed bioprinter manufacturer that is committed to advancing the field of regenerative medicine and bettering the quality of life of people around the world.
The field of bioprinting is an extremely new one, but it shows great promise. Simply, it is the automated, computer aided deposition of bio-materials (which are cells, growth factors, and biocompatible polymers) for the manufacturing of functional human tissues or organs. Growth factors are harvested and used with a proprietary printing technology to create or regenerative damaged or diseased organs. Rokit Healthcare does this primarily through the proliferation of a machine that they dub an ‘organ regenerator’– it looks like a 3D printer, but instead of using plastics to create things, they use cells and materials that will be safe to implant within the human body.
The process of 3D bioprinting human tissues and organs is a revolutionary technology in the field of tissue engineering. One of the major challenges in regenerative medicine research and tissue engineering is mimicking the micro and macro environment of human tissues. In response to this challenge, advances in additive manufacturing have inspired scientists in Korea to develop novel bioprinting technology, for human tissues and organs.
With the advancements of 3D printing and regenerative medicine working together, the potential is seemingly limitless for the spreading of bioprinting technology, a process that is known as 4D Printing– and Global Stem Cells Group, in an effort make this revolutionary technology available to patients, has forged an agreement with Rokit Healthcare to promote, and distribute the company’s technology in Latin America-
The Invivo 4D Printer is Rokit Healthcare’s flagship product, and it is one that revolutionizes the application of regenerative medicine and growth factor-based therapies. creating a solution for personalized and improved patient care. By leveraging a combination of 3D and bioprinting technologies, it can better distribute a patient’s autologous tissues and cells, making it an invaluable tool for those that are looking to improve the efficacy of their results, especially for certain dermatological conditions including scarring.
“We’re extremely excited about this new opportunity and look forward to working with Rokit,” Says Benito Novas, CEO of the Global Stem Cells Group, “The Invivo 4D Printer is in a position to turn the practice of regenerative medicine onto its head, and we are planning on creating a training center in Cancun, Mexico exclusively to showcase and instruct other physicians in this cutting-edge technology,”
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for regenerative medicine solutions that adhere to the highest medical standards.
About ROKIT :
ROKIT Healthcare is a global healthcare company that is committed to providing an effective and autologous organ regeneration platform. In order to undertake this daunting task, the company uses proprietary biofabrication technologies that show promise in treating several types of diseases in the field of regenerative medicine. Through the proliferation of 4D bioprinting technology, autologous stem cell technologies, ROKIT Healthcare believes that supplying an avenue for organ regeneration will drastically change the way that everyday people trust and manage their own body.
The group is sponsoring the event, which will attract physicians from across the globe with an interest in longevity and anti-aging medicine
MIAMI LAKES, Florida— The Global Stem Cells Group (GSCG) is set to sponsor the XI Congreso Mundial de Medicina Antienvejecimiento y Longevidad (World Conference of Anti-Aging and Longevity Medicine) to be held in Mexico City, Mexico on February 16-18, 2020.
The medical congress is expected to attract over 450 physicians and researchers from across the world interested in anti-aging and longevity practices and medical innovations. Over 30 speakers are slated to share information with attendees on a wide range of topics on how to lead a long, healthy life and improve longevity.
The GSCG is set to share a number of its latest innovations with congress attendees, including its newly released GCell technology device. This cutting-edge tool utilizes micrograft technology to harness the natural and powerful restorative capabilities of adipose tissues. Because it is FDA compliant, the device allows physicians across the globe to continue practicing adult stem cells-based procedures.
Additional benefits of GCell technology include shorter treatment times, delivering in-office treatments in around 30 minutes with local anesthesia, as well as less fat collection compared to existing treatments (15 mL versus 50 mL). GCell technology holds exciting implications across a range of medical specialties, including orthopedics, dermatology, cosmetic gynecology, aesthetics, and hair loss.
In addition to its GCell technology, the GSCG will also feature its newest line of stem cells products derived from first-tissue exosomes. Cellgenic Flow Exosomes utilizes the latest science and research available in cellular therapies to deliver a non-surgical approach to creating regenerative responses in a broad range of treatments. The product utilizes exosomes, which replicate the signals given out by stem cells, versus actual stem cells. Exosomes play a pivotal role in cell-to-cell communication and are involved in a wide range of physiological processes. These particles transfer critical bioactive molecules such as proteins, mRNA, and miRNA between cells and regulate gene expression in recipient cells.
“The XI Congreso Mundial de Medicina Antienvejecimiento y Longevidad is one of the world’s premier events connecting physicians and researchers with today’s most innovative treatments and technologies utilizing regenerative medicine,” said Benito Novas, CEO of the GSCG. “As a worldwide leader in training, education, and innovative products in the field of regenerative medicine, the GSCG is pleased to sponsor this congress and share its exciting new portfolio of products with physicians from across the world.”
To learn more about the Global Stem Cells Group and all of the group’s latest news and innovations, visit http://www.stemcellsgroup.com/
The group is set to sponsor the 2nd Congress of Aesthetic Medicine and Regenerative Gynecology to be held in Paraguay
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG) has announced its sponsorship of the 2nd Congress of Aesthetic Medicine and Regenerative Gynecology to be held on March 12-13, 2020 in Asuncion, Paraguay. The GSCG’s CEO Benito Novas and Development and Research Director Dra. Maritza Novas will each deliver key lectures during the annual medical congress, which will focus on advancements in the fields of aesthetic medicine and regenerative gynecology.
Benito Novas serves as the GSCG’s CEO and will lead a lecture on regenerative medicine marketing strategies. His talk will give practical marketing tools and advice to physicians running their own private practices in aesthetic medicine. In addition to his role as CEO with the GSCG, Novas also serves as the Head of Public Relations for the International Society for Stem Cell Application (ISSCA) and has authored two books on marketing strategies for clinics in the regenerative medicine industry, Your Aesthetic Practice: What Your Patients Are Saying and Marketing Digital en Su Clínica Estética (https://www.thriftbooks.com/a/benito-novas/2752773/).
Dra. Maritza Novas serves as the GSCG’s Development and Research Director as well as the US Director for the ISSCA. She will deliver the opening lecture for the congress, discussing clinical applications of regenerative medicine in the aesthetic field. Her lecture will be informed by clinical case studies demonstrating the efficacy of regenerative treatments in aesthetics. Dra. Novas is well-renowned in the field of regenerative medicine for making a profound impact on her patients through innovative treatment protocols. She has additionally trained countless doctors looking to add regenerative medicine to their practices.
On March 14, following the conclusion of the congress, representatives from the GSCG will also offer a certification course in cellular therapy. The course is designed to help all physicians who want to add stem cells therapies based on birth tissue derived components to their practices. Attendees will learn about the latest stem cell products, such as exosomes, cord blood, and amniotic fluid. Additional topics to be covered will include how to choose the right products to treat specific conditions and details about how to handle the manufacturing process, from selecting a healthy donor through quality control and storage at the medical office.
“The Global Stem Cells Group is pleased to serve as a sponsor for the 2nd Congress of Aesthetic Medicine and Regenerative Gynecology,” said Benito Novas. “We look forward to sharing today’s best research on marketing strategies to help regenerative medicine practices grow their success and influence as well as sharing clinical applications of stem cells treatments in aesthetic medicine. As a global leader in stem cells education, we always look forward to these events to help more physicians gain the knowledge and skills necessary to bring life-saving treatments to more patients across the globe.”
The group will launch its innovative GCell technology and a new online course at the event, while CEO Benito Novas will lead a lecture about marketing in the regenerative medicine field
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG) is set to sponsor the Second Intercontinental Medical Congress on Anti-Aging and Longevity (https://miami2020.semal.org/) hosted by the Spanish Society of Anti-Aging Medicine (SEMAL) and the Federation of Latin American of Anti-Aging Medicine (FISMAL). The congress will be held on February 6-9, 2020 in Miami, Florida at the Hampton Inn & Suites by Hilton Miami Brickell.
During the event, the Global Medical Group, a subsidiary of GSCG, will launch its GCell micrograft technology, an autologous tissue suspension that boasts minimal manipulation. The product has application implications for a wide range of medical uses, including orthopedics, dermatology, cosmetic gynecology, aesthetics, and hair loss.
GCell technology will allow physicians utilizing regenerative medicine to continue practicing adult stem cells-based procedures thanks to the product’s adherence to FDA compliance standards since the procedure does not utilize enzymes.
GCell technology is a closed-system medical device that harnesses the natural and powerful restorative capabilities of adipose tissue. The GCell SVF (Stromal Vascular Fraction) procedure can be performed in office in around 30 minutes, while existing procedures can take up to two hours. It also utilizes only local anesthesia, and performing physicians only have to collect 15 ml of fat instead of the 50 ml required for traditional protocols.
During the congress, the GSCG will also be launching its new online stem cells course, which will benefit doctors interested in learning about the newest stem cells protocols and technologies. The course will specifically focus on stem cells protocols based on first tissue derived compounds, such as exosomes, cord blood, and amniotic fluid.
In addition to launching GCell technology and its new course, the GSCG’s CEO and founder Benito Novas will be giving a lecture in the main room. He will be speaking to attendees about the newest challenges facing the regenerative medicine filed and what types of marketing strategies practitioners should implement to run a successful practice integrating regenerative medicine.
“The Global Stem Cells Group is looking forward to attending the Second Intercontinental Medical Congress on Anti-Aging and Longevity to talk with attending physicians and researchers about the technological and educational advances we are making to help move the field of regenerative medicine forward,” said Novas.
To learn more about the Global Stem Cells Group and all of the group’s latest news and innovations, visit http://www.stemcellsgroup.com/.
The agreement between Global and CHU Mohammed VI in Marrakech will help enhance staff preparation and clinical offerings in regenerative medicine
MIAMI LAKES, Florida— Stem Cells Training Inc., a subsidiary of the Global Stem Cells Group (GSCG), has announced that it has signed an onsite training agreement with Centre Hospitalo-Universitaire Mohammed VI Marrakech (CHU). GSCG faculty will travel to Marrakech, Morocco to provide this invaluable two-day training to CHU’s staff on February 14 and 15, 2020.
The agreement names the GSCG as CHU’s provider of training for the facility’s regenerative medicine staff. Through the deal, the GSCG will provide preparation and education in the latest regenerative medicine techniques and stem cells protocols, focusing on those utilizing adult stem cells and birth tissue derived from stem cells. In addition to on-site training, the agreement also names the GSCG as CHU’s provider for all necessary equipment to implement regenerative medicine treatments.
The additional training and supplies offered through the agreement will allow CHU to incorporate the industry’s most effective stem cells protocols into the hospital’s treatment options.
The Centre Hospitalo-Universitaire Mohammed VI is a regional leader in quality patient care, student education, physician training, and innovative medical research. Located in Marrakech, CHU provides the bustling city with short-, medium-, and long-range care solutions. Counted among its innovative institutional projects, CHU’s Culture and Health program is committed to making the hospital a more human environment for patients seeking care.
“The agreement between the Global Stem Cells Group and the Centre Hospitalo-Universitaire Mohammed VI Marrakech is an important one for both partners,” said Benito Novas, CEO of the Global Stem Cells Group. “As a university institution, CHU is interested in leading clinical trials to prove the safety and efficacy of regenerative medicine treatment protocols—something the GSCG has a vested interest in. This agreement will allow us to train hospital staff to offer cutting-edge treatments to patients in Morocco while helping stem cells treatments gain more traction globally, making them more viable options for physicians to incorporate into their practices.”
With the newly signed agreement, the GSCG continues to advance its mission to expand its presence across the global, especially focusing on North America and the Middle East. Physicians looking to grow their practices by offering regenerative medicine treatments can benefit from the GSCG’s trainings, which are conveniently held onsite at physicians’ home facilities, no matter where they are located globally.
To learn more about the onsite training opportunities offered by the Global Stem Cells Group, visit https://www.stemcelltraining.net/onsitetraining/. To learn more about the Centre Hospitalo-Universitaire Mohammed VI Marrakech, visit www.chumarrakech.ma.
The group will host six events across the globe, combining networking and education for practitioners of regenerative medicine
MIAMI LAKES, Florida— The International Society for Stem Cell Application (ISSCA), a worldwide leader in regenerative medicine education, has announced its slate of 2020 medical congresses. The group’s calendar includes dates at six locations across the globe
Through its congresses, the ISSCA seeks to create a platform through which physicians can collaborate, share data, initiate discussions, and exchange information that may be directly translated to therapeutic applications. All doctors who want to share their medical research are welcome to attend, and the ISSCA welcomes abstract submissions and reviews them on a continuing basis.
For the second year straight, the main topic discussed at ISSCA’s congresses will be how cellular products derived from birth tissue (allogeneic compounds) have revolutionized the industry by delivering safer, shorter stem cells procedures for practitioners. During each event, lecturers will respond to concerns attendees have about how regenerative medicine advances will satisfy FDA regulations and how new technologies could continue to help patients under new FDA laws.
This year, the ISSCA welcomes three new cities to its agenda—Salvador de Bahia, Brazil; Punta del Este, Uruguay; and Jakarta, Indonesia. The six congresses are as follows:
- May 2020: Mexico City, Mexico
- June 2020: Caracas, Venezuela
- August 2020: Salvador de Bahia, Brazil
- October 2020: Buenos Aires, Argentina
- November 2020: Jakarta, Indonesia
- December 2020: Punta del Este, Uruguay
“We at the ISSCA are looking forward to this year’s calendar of congresses, which will provide invaluable networking and educational opportunities to physicians looking to expand their knowledge on current innovations and best practices concerning regenerative medicine,” noted Benito Novas, ISSCA VP of Public Relations. “Our global congresses expand on ISSCA’s mission to continue to serve as the premier educational resource for physicians across the globe looking to introduce stem cells treatments into their practices.”
To learn more about the ISSCA or to register for an upcoming congress, visit www.issca.us.
Global Stem Cells Group Releases New Product to Meet Growing Demand for Birth Tissue Derived Compounds
Cellgenic Flow Exosomes has a wide range of therapeutic implications, including hair loss and pain management
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG) has announced the release of a new product in response to growing demands from regenerative medicine practitioners for cellular products derived from birth tissue. The product, Cellgenic Flow Exosomes, is 100% natural and is available in a 1 mL vial comprised of 5 billion exosomes per mL and is currently manufactured in Mexico and in Global’s US-based facilities.
As the popularity and efficacy of stem cells treatments increase across the globe, the demand for cellular products like Cellgenic have also increased. With this demand in mind, the GSCG–a global leader in stem cell research, patient application, and physician training–sought to create an innovative cellular product to meet the needs of physicians looking to offer regenerative medicine treatments in their existing practices.
Cellgenic is primarily comprised of exosomes, cell-derived non-particles that play a pivotal role in cell-to-cell communication that are involved in a wide range of physiological processes. Exosomes play an important role in the transfer of proteins, mRNA, miRNA, and other bioactive molecules between cells and regulate gene expression in recipient cells, thus influencing various molecular pathways.
An increasing amount of attention has been paid to exosomes in recent years thanks to the wide range of therapeutic implications they may hold. Some of the most effective uses for exosomes have come in hair therapy and pain management.
Using Cellgenic as a treatment for hair loss has resulted in prominent hair growth results in both men and women. It is highly recommended for those who are too young for hair transplant surgery and for those within the earlier stages of the hair loss cycle.
In terms of pain management, Cellgenic has shown promise in delivering relief from pain and discomfort and may potentially stimulate repair as opposed to blocking or masking them. Common pain and degenerative conditions that Cellgenic may help treat include osteoarthritis, knee pain, shoulder pain, nerve pain, tendonitis, and slow- and non-healing wounds and burns.
For doctors who are interested in learning more about Cellgenic, the GSCG has developed an online course to provide them with the relevant knowledge needed to make a decision about incorporating allogeneic compounds into their treatment protocols.
“Global’s newest product innovation, Cellgenic Flow Exosomes, is an exciting addition to our product portfolio,” said Benito Novas, CEO of the Global Stem Cells Group. “Our goal is to continually innovate and meet the demands of physicians practicing regenerative medicine by providing cutting-edge therapies for those suffering from degenerative diseases. The release of our Cellgenic product accomplishes this goal while also contributing to our mission of being a leader in stem cells research.”
To learn more about Cellgenic Flow Exosomes, visit https://cellgenic.com/.